{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:05:50Z","timestamp":1789153550385,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.euo.2024.11.014","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T20:31:42Z","timestamp":1733862702000},"page":"829-840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Is Frequent Imaging Necessary? Impact of Computed Tomography During Follow-up After Surgical Treatment for Nonmetastatic Renal Cell Carcinoma: A Systematic Review"],"prefix":"10.1016","volume":"8","author":[{"given":"Luna","family":"van den Brink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlin A.A.","family":"Reijerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.E.L.","family":"Henderickx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Bex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faridi S.","family":"Jamaludin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrie P.","family":"Beerlage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto M.","family":"van Delden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reindert J.A.","family":"van Moorselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Stoker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shandra","family":"Bipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia J.","family":"Zondervan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.11.014_b0005","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.11.014_b0010","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.3390\/cancers14164059","article-title":"Epidemiology and prevention of renal cell carcinoma","volume":"14","author":"Makino","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2024.11.014_b0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of renal cell carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J Oncol"},{"key":"10.1016\/j.euo.2024.11.014_b0020","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1586\/14737140.7.6.847","article-title":"Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection","volume":"7","author":"Breda","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.euo.2024.11.014_b0025","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0094-0143(03)00056-9","article-title":"Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease","volume":"30","author":"Janzen","year":"2003","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.euo.2024.11.014_b0030","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.euf.2018.02.010","article-title":"Long-term outcomes of follow-up for initially localised clear cell renal cell carcinoma: RECUR database analysis","volume":"5","author":"Dabestani","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2024.11.014_b0035","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.11.014_b0040","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2024.11.014_b0045","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/JU.0000000000001912","article-title":"Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: part II","volume":"206","author":"Campbell","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.11.014_b0050","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1200\/JCO.2017.73.5324","article-title":"Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma","volume":"35","author":"Motzer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.11.014_b0055","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2017.09.008","article-title":"Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results","volume":"73","author":"Motzer","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.11.014_b0060","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","article-title":"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial","volume":"401","author":"Motzer","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.11.014_b0065","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.11.014_b0070","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.11.014_b0075","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","article-title":"Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"387","author":"Haas","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.11.014_b0080","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdy454","article-title":"Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial","volume":"29","author":"Gross-Goupil","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.11.014_b0085","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/cncr.11234","article-title":"Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials","volume":"97","author":"Leibovich","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2024.11.014_b0090","first-page":"14","article-title":"Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). Scand","volume":"53","author":"Dabestani","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.11.014_b0095","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1200\/JCO.2014.56.5416","article-title":"Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines","volume":"32","author":"Stewart","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.11.014_b0100","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1001\/archinternmed.2009.427","article-title":"Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer","volume":"169","author":"Smith-Bindman","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.euo.2024.11.014_b0105","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.juro.2015.12.094","article-title":"Comparison of renal cell carcinoma surveillance guidelines: competing trade-offs","volume":"195","author":"Lobo","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.11.014_b0110","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00345-018-2415-3","article-title":"Quality of life outcomes in patients with localised renal cancer: a literature review","volume":"36","author":"Rossi","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2024.11.014_b0115","unstructured":"The Cochrane Collaboration Prognosis Methods Group. Review tools. 2018."},{"key":"10.1016\/j.euo.2024.11.014_b0120","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2024.11.014_b0125","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(23)00913-3","article-title":"Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"402","author":"Ryan","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.11.014_b0130","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.11.014_b0135","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.eururo.2020.12.029","article-title":"Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: final overall survival analysis of the phase 3 PROTECT trial","volume":"79","author":"Motzer","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.11.014_b0140","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.11.014_b0145","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.eururo.2015.12.004","article-title":"Five-year oncologic outcomes after transperitoneal robotic partial nephrectomy for renal cell carcinoma","volume":"69","author":"Andrade","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.11.014_b0150","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.eururo.2019.04.026","article-title":"Oncologic outcomes following partial nephrectomy and percutaneous ablation for cT1 renal masses","volume":"76","author":"Andrews","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.11.014_b0155","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.eururo.2007.11.007","article-title":"Nephron-sparing surgery versus radical nephrectomy in the treatment of intracapsular renal cell carcinoma up to 7 cm","volume":"53","author":"Antonelli","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.11.014_b0160","first-page":"12130","article-title":"Oncological and functional outcomes of patients who underwent open partial nephrectomy for kidney tumor","volume":"95","author":"Bosnal\u0131","year":"2023","journal-title":"Arch Ital Urol Androl"},{"key":"10.1016\/j.euo.2024.11.014_b0165","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3233\/KCA-230019","article-title":"Comparison of oncological and functional outcomes of radical versus partial nephrectomy for cT1b renal cell carcinoma: a two-centre, matched analysis","volume":"8","author":"van den Brink","year":"2024","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.euo.2024.11.014_b0170","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.eururo.2006.05.022","article-title":"Simple enucleation for the treatment of PT1a renal cell carcinoma: our 20-year experience","volume":"50","author":"Carini","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.11.014_b0175","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1007\/s00330-022-08719-1","article-title":"Long-term outcomes of image-guided ablation and laparoscopic partial nephrectomy for T1 renal cell carcinoma","volume":"32","author":"Chan","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.euo.2024.11.014_b0180","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/JCMA.0000000000000501","article-title":"Predictive factors for disease recurrence in patients with locally advanced renal cell carcinoma treated with curative surgery","volume":"84","author":"Chang","year":"2021","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.euo.2024.11.014_b0185","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/iju.12283","article-title":"Partial nephrectomy versus radical nephrectomy for non-metastatic pathological T3a renal cell carcinoma: a multi-institutional comparative analysis","volume":"21","author":"Oh","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2024.11.014_b0190","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1245\/s10434-021-11133-4","article-title":"Long-term oncological and functional outcomes after robot-assisted partial nephrectomy for clinically localized renal cell carcinoma","volume":"29","author":"Otaola-Arca","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.euo.2024.11.014_b0195","first-page":"44","article-title":"Oncological and functional outcomes of laparoscopic radiofrequency ablation and partial nephrectomy for T1a renal masses: a retrospective single-center 60 month follow-up cohort study","volume":"16","author":"Park","year":"2019","journal-title":"Urol J"},{"key":"10.1016\/j.euo.2024.11.014_b0200","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.euf.2020.10.011","article-title":"Outcomes of robot-assisted partial nephrectomy for clinical T3a renal masses: a multicenter analysis","volume":"7","author":"Yim","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2024.11.014_b0205","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1148\/radiol.2020190919","article-title":"Percutaneous microwave ablation versus laparoscopic partial nephrectomy for cT1a renal cell carcinoma: a propensity-matched cohort study of 1955 patients","volume":"294","author":"Yu","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.euo.2024.11.014_b0210","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00345-018-2208-8","article-title":"Long-term oncological outcomes after robotic partial nephrectomy for renal cell carcinoma: a prospective multicentre study","volume":"36","author":"Beauval","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2024.11.014_b0215","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.eururo.2018.10.007","article-title":"Intensive imaging-based follow-up of surgically treated localised renal cell carcinoma does not improve post-recurrence survival: results from a European Multicentre Database (RECUR)","volume":"75","author":"Dabestani","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.11.014_b0220","doi-asserted-by":"crossref","first-page":"660.e1","DOI":"10.1016\/j.urolonc.2017.06.052","article-title":"Imaging strategy and outcome following partial nephrectomy","volume":"35","author":"Mouracade","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.11.014_b0225","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/bju.12246","article-title":"Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma\u2013results from a comprehensive multi-centre database (CORONA\/SATURN-Project)","volume":"112","author":"Brookman-May","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.11.014_b0230","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1464-410X.2008.08233.x","article-title":"Impact of clinical variables on predicting disease-free survival of patients with surgically resected renal cell carcinoma","volume":"103","author":"Brookman-Amissah","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.11.014_b0235","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(16)30196-6","article-title":"Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial","volume":"17","author":"Rini","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.11.014_b0240","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.juro.2008.11.112","article-title":"Oncological followup after radical cystectomy for bladder cancer-is there any benefit?","volume":"181","author":"Volkmer","year":"2009","journal-title":"J Urol"},{"issue":"6_Suppl","key":"10.1016\/j.euo.2024.11.014_b0245","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1158\/1538-7445.AM2024-5151","article-title":"Abstract 5151: High serum kidney injury marker-1 and high baseline tumor PD-L1 protein expression levels are independently associated with treatment effect in adjuvant nivolumab plus ipilimumab vs placebo in localized clear cell renal cell carcinoma","volume":"84","author":"Vemula","year":"2024","journal-title":"Cancer Res"},{"issue":"6_Suppl","key":"10.1016\/j.euo.2024.11.014_b0250","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1158\/1538-7445.AM2024-5151","article-title":"Abstract 5151: High serum kidney injury marker-1 and high baseline tumor PD-L1 protein expression levels are independently associated with treatment effect in adjuvant nivolumab plus ipilimumab vs placebo in localized clear cell renal cell carcinoma","volume":"84","author":"Vemula","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2024.11.014_b0255","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1016\/S2666-1683(20)36248-0","article-title":"P081 - Glycosaminoglycan (GAG) scores for surveillance of recurrence in Leibovich Points \u22655 non-metastatic clear cell renal cell carcinoma: AURORAX-0087A trial in progress report","volume":"21","author":"Dabestani","year":"2020","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2024.11.014_b0260","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1200\/JCO.2015.61.8009","article-title":"Oncologic surveillance after surgical resection for renal cell carcinoma: a novel risk-based approach","volume":"33","author":"Stewart-Merrill","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.11.014_b0265","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/bco2.266","article-title":"A protocol for the development of core outcome sets for effectiveness trials and clinical audits in renal cell cancer (R-COS)","volume":"4","author":"MacLennan","year":"2023","journal-title":"BJUI Compass"},{"key":"10.1016\/j.euo.2024.11.014_b0270","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1148\/radiol.2481071451","article-title":"Effective doses in radiology and diagnostic nuclear medicine: a catalog","volume":"248","author":"Mettler","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.euo.2024.11.014_b0275","doi-asserted-by":"crossref","first-page":"246.e1","DOI":"10.1016\/j.urolonc.2024.03.008","article-title":"Cost of upper tract imaging obtained during hematuria evaluation: analysis of a national claims database","volume":"42","author":"Hannemann","year":"2024","journal-title":"Urol Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T16:55:32Z","timestamp":1748451332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124002761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2588931124002761"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.11.014","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is Frequent Imaging Necessary? Impact of Computed Tomography During Follow-up After Surgical Treatment for Nonmetastatic Renal Cell Carcinoma: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}